{
    "2019-09-04": [
        [
            {
                "time": "",
                "original_text": "【东吴医药】医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业增速",
                        "龙头引领",
                        "创新药产业链",
                        "创新生物制品",
                        "医疗服务"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "83只超级牛股最新评级 这些公司目标涨幅空间还有30%以上（名单）",
                "features": {
                    "keywords": [
                        "超级牛股",
                        "目标涨幅",
                        "30%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中信建投秋季轻工策略：坚守优势赛道及龙头公司",
                "features": {
                    "keywords": [
                        "中信建投",
                        "秋季策略",
                        "轻工",
                        "优势赛道",
                        "龙头公司"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "轻工制造"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物9月投资逻辑：核心资产仍为投资方向，优选业绩增长加速或估值合理标的",
                "features": {
                    "keywords": [
                        "医药生物",
                        "9月投资逻辑",
                        "核心资产",
                        "业绩增长",
                        "估值合理"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}